Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The CD4 binding site is a highly conserved region on the HIV envelope glycoprotein gp120. This site is essential for the virus’s ability to attach to and enter host cells, specifically by binding to the CD4 receptor found primarily on helper T-cells. The interaction between gp120 and CD4 initiates a cascade of conformational changes in both gp120 and its partner subunit, gp41, ultimately leading to fusion of the viral membrane with the host cell membrane and entry of viral genetic material. Targeting this site is a major approach for developing neutralizing antibodies and small-molecule inhibitors to block viral entry.
Blocks viral entry by preventing gp120-CD4 interaction
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CD4 Binding Site (HIV Envelope) (CD4 Binding Site).